Core Viewpoint - The DT New Leaf Award is a global, professional, and comprehensive award focused on innovation in the bio-based sector, often referred to as the "Oscar of the bio-based industry" [2]. Group 1: Award Overview - The DT New Leaf Award features four main categories: Innovation Materials Award, Innovation Application Award, Most Commercially Valuable Award, and Innovative Industry Solutions Award [2]. - Free registration for the award is open until March 13 [2]. Group 2: Participating Companies and Products - Over 40 listed and representative companies have registered for the 2026 DT New Leaf Award, including notable firms such as Wanhua Chemical, Shuangqiang Technology, and Yutong Technology [3]. - Wanhua Chemical (600309) is a leading global chemical new materials company and has established a bio-based polyurethane industry chain [5]. - Shuangqiang Technology (001211) is recognized as China's first publicly listed chopstick company and has partnered with Ningbo Materials to develop bamboo-based composite logistics pallets, showcasing significant market potential [7]. - China Resources Double Crane (600062) has its 1,4-butanediamine included in the Ministry of Industry and Information Technology's list of landmark bio-manufacturing products, having completed pilot tests [9]. Group 3: Product Innovations - Wanhua Chemical's PCDL product utilizes dimethyl carbonate as a raw material, produced through carbon capture technology, and exhibits excellent mechanical properties [11]. - The bamboo-based composite pallets developed by Shuangqiang Technology demonstrate high rigidity and toughness, with costs only 60%-70% of traditional plastic pallets [12]. - Yutong Technology is advancing the development of non-wood fiber, bio-adhesives, and bio-waxes, filling domestic technological gaps with products like biodegradable cat litter [13]. Group 4: Future Prospects and Collaborations - Lifebio is a global leader in PEF & FDCA and has partnered with leading companies to develop a production line for FDCA, with an investment of 1 billion yuan expected to yield an annual output of 15,000 tons [16]. - Zhongke Guosheng is completing a 200 million yuan A+ round of financing and is set to achieve mass production of FDCA by 2026 [17]. - Fengyuan Bio is recognized as a "chain leader" in the bio-based materials industry, utilizing non-grain technology to convert straw into mixed sugars for lactic acid production [19]. Group 5: Technological Innovations - Guwei Yuan Chuang is the first global company to focus on non-grain bio-based succinic acid production, recently receiving ISCC PLUS certification for its innovative processes [21]. - The company has developed a high-efficiency cell factory for the synthesis of bio-based 1,4-butanediamine, achieving over 98% purity and a 60% reduction in carbon emissions [22]. - The innovative use of plant fiber materials in the production of biodegradable packaging solutions is gaining traction, with several companies showcasing advancements in this area [23][24].

Core Viewpoint - The DT New Leaf Award is a global, professional, and comprehensive award focused on innovation in the bio-based sector, often referred to as the "Oscar of the bio-based industry" [2]. Group 1: Award Overview - The DT New Leaf Award features four main categories: Innovation Materials Award, Innovation Application Award, Most Commercially Valuable Award, and Innovative Industry Solution Award [2]. - Free registration for the award is open until March 13 [2]. Group 2: Participating Companies - Over 40 listed and representative companies have registered for the 2026 DT New Leaf Award, including notable firms such as Wanhua Chemical, Shuangqiang Technology, and Yutong Technology [3]. - Wanhua Chemical is recognized as a leading global chemical new materials company and has established a bio-based polyurethane industry chain [5]. - Shuangqiang Technology, known as the first stock of chopsticks in China, has partnered with Ningbo Materials to develop bamboo-based composite logistics pallets, showcasing significant market potential [7]. Group 3: Selected Products and Innovations - Wanhua Chemical's PCDL product utilizes dimethyl carbonate as a raw material, produced through carbon capture technology, and exhibits excellent mechanical properties [11]. - Shuangqiang Technology's bamboo-based composite pallets are noted for their high rigidity and toughness, with costs only 60%-70% of traditional plastic pallets [12]. - Huazhong University of Science and Technology's team has developed a unique liquid gel foaming technology aimed at producing 100% biodegradable gel foam materials [78]. Group 4: Industry Trends and Developments - The bio-based materials sector is seeing significant innovations, such as the development of bio-based 1,4-butanediamine by Huazhong University, which has been recognized in the Ministry of Industry and Information Technology's list of landmark bio-manufacturing products [9][10]. - Companies like Lifebio and Zhongke Guosheng are advancing in the production of bio-based chemicals and materials, with Lifebio's FDCA production line expected to yield 15,000 tons annually after reaching full capacity [16][17]. Group 5: Award Process and Evaluation - The award process includes registration, online voting for preliminary selection, and expert reviews for final selection, culminating in an award ceremony on May 21 [110]. - Evaluation criteria for the awards include innovation, application, functionality, commercial value, and sustainability, with different weightings for each category [111].

Core Viewpoint - China Resources Double Crane Pharmaceutical Co., Ltd. has announced that several of its drugs are expected to be selected in the continuation procurement organized by the National Organization for Drug Procurement, which is set to stabilize or further reduce prices while enhancing the selection power of medical institutions [1][4]. Group 1: Selected Drugs - The company participated in the continuation procurement for drugs whose agreements have expired, with several key products expected to be selected, including those that rank among the top five in revenue [1][2]. - The procurement cycle for the selected drugs will last until December 31, 2028 [1]. Group 2: Financial Impact - In 2024, the sales revenue for Valsartan Hydrochlorothiazide Tablets is projected to be 517 million yuan, accounting for 4.61% of the total revenue; for Nifedipine Controlled-Release Tablets, it is expected to be 147 million yuan, or 1.31% [3]. - For the first three quarters of 2025, the sales revenue for Valsartan Hydrochlorothiazide Tablets is estimated at 426 million yuan, representing 5.14% of total revenue; for Nifedipine Controlled-Release Tablets, it is projected at 138 million yuan, or 1.67% [3]. Group 3: Market Dynamics - The continuation procurement is expected to maintain price stability or further decrease prices, allowing medical institutions greater choice among selected suppliers, which may help ensure continuity in clinical medication and reduce risks associated with drug switching [4]. - Although the selection may lead to a decrease in overall sales revenue, it is anticipated that the company can solidify its existing market share and potentially increase its market penetration due to its brand influence and reliable supply capabilities [4].

Core Points - The DT New Leaf Award is a global, professional, and comprehensive award focused on innovation in the bio-based sector, often referred to as the "Oscar of the bio-based industry" [2] - The award features four categories: Innovation Material Award, Innovation Application Award, Most Commercially Valuable Award, and Innovative Industry Solution Award [2] - The deadline for free registration is March 13 [2] Group 1: Participating Companies and Products - Over 40 listed and representative companies have registered for the 2026 DT New Leaf Award, including major players in bio-based materials and applications such as Wanhua Chemical, Shuangqiang Technology, and Yutong Technology [3] - Wanhua Chemical (600309) is a leading global chemical new materials company and has established a bio-based polyurethane industry chain [5] - Shuangqiang Technology (001211) is recognized as the first stock of chopsticks in China and has signed a contract to jointly develop bamboo-based composite materials with Ningbo Materials [7] - China Resources Double Crane (600062) has its 1,4-butanediamine included in the "Ministry of Industry and Information Technology's list of landmark bio-manufacturing products" [9] Group 2: Selected Products and Innovations - Wanhua Chemical's PCDL product, made from dimethyl carbonate, can be produced through carbon capture processes and has excellent mechanical properties [11] - Shuangqiang Technology's bamboo-based composite logistics pallets are cost-effective, priced at only 60%-70% of traditional plastic pallets with similar performance [12] - Yutong Technology is advancing the development of non-wood fibers and biodegradable materials, including eco-friendly cellulose films and plant-based cat litter [13] - Lifebio is a global leader in PEF & FDCA and has a production line for FDCA with an investment of 1 billion yuan, expected to yield an annual output of 15,000 tons [16] Group 3: Innovations and Technologies - Zhongke Guosheng is a representative enterprise in the HMF-FDCA-PEF full industry chain and has completed a 200 million yuan A+ round financing [17] - Fengyuan Bio is recognized as a "chain leader" in the bio-based materials industry, utilizing non-grain technology to convert straw into mixed sugars at a cost significantly lower than corn glucose [19] - Guwei Yuan Chuang is the first global company to focus on non-grain bio-based succinic acid production and has received the first ISCC PLUS certification for its products [21] - The innovative use of plant fiber materials in products like Ecocoon and PEF-based fibers demonstrates advancements in sustainable materials with multiple natural functions [23][24] Group 4: Award Evaluation and Process - The evaluation criteria for the awards include technical innovation, application innovation, functionality, commercial value, and sustainability [111] - The total score for the awards is 100 points, with online voting accounting for 20 points and expert reviews for 80 points [110] - The award process includes registration, online voting, and expert evaluations, culminating in a ceremony on May 21 [110]

证券代码：600062 证券简称：华润双鹤 公告编号：临 2026－010 华润双鹤药业股份有限公司 关于公司部分药品在国家组织集采药品协议期满品种 接续采购中拟中选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 2026 年 2 月 9 日，华润双鹤药业股份有限公司(以下简称"公司") 及部分下属子公司参加了国家组织集采药品协议期满品种接续采购 办公室(以下简称"接续采购办公室")组织的集采药品协议期满品种 接续采购(以下简称"本次接续采购")。根据接续采购办公室于 2026 年 2 月 10 日发布的《国家组织集采药品协议期满品种接续采购拟中 选结果公示》，公司部分药品拟中选本次接续采购。现将相关情况公 告如下： | 拟中选企业 | 品种名称 | 药品适应症 | 规格 | | --- | --- | --- | --- | | 华润双鹤药业 股份有限公司 | 缬沙坦氢氯 噻嗪片 | 治疗单一药物不能充分控制血压的轻-中 | 每片含缬沙坦 80mg，氢氯噻 | | | | 度原发性高血压 | 嗪 12.5mg | ...

Core Viewpoint - The company, China Resources Double Crane (华润双鹤), is participating in a national procurement process for pharmaceutical products, with some of its drugs expected to be selected in the upcoming procurement results, which will be implemented by the end of March 2026 [1][2] Group 1: Company Performance - In the first three quarters of 2025, the sales revenue of Valsartan and Hydrochlorothiazide tablets was 426 million yuan, accounting for 5.14% of the total revenue [1] - The sales revenue of Nifedipine Controlled-Release Tablets was 138 million yuan, representing 1.67% of the total revenue [1] - The sales revenue of Enoxaparin Sodium Injection was 119 million yuan, making up 1.43% of the total revenue [1] - The sales revenue of Nifedipine Sustained-Release Tablets (II) was 108 million yuan, accounting for 1.30% of the total revenue [1] - The sales revenue of Irbesartan Dispersible Tablets was 79 million yuan, which is 0.95% of the total revenue [1] Group 2: Industry Context - The upcoming procurement process aims to maintain stable or decreasing prices, providing medical institutions with greater choice among selected suppliers, which helps ensure continuity in clinical medication and reduces the risk of medication switching due to centralized procurement [2] - Although the selection may lead to a decrease in overall sales revenue, it is expected to solidify the company's existing market share, with potential for increased market penetration due to brand influence and reliable supply capabilities [2]

Core Viewpoint - China Resources Double Crane announced that the company and some subsidiaries participated in the national organized procurement for drugs whose agreements are expiring, with several drugs expected to be selected for procurement [1] Group 1: Selected Drugs and Revenue Impact - The main drugs expected to be selected include: - Valsartan and Hydrochlorothiazide Tablets with projected sales revenue of 517 million yuan, accounting for 4.61% of the 2024 annual revenue [1] - Nifedipine Controlled-Release Tablets with projected sales revenue of 147 million yuan, accounting for 1.31% of the 2024 annual revenue [1] - Enoxaparin Sodium Injection with projected sales revenue of 128 million yuan, accounting for 1.14% of the 2024 annual revenue [1] - Nifedipine Sustained-Release Tablets (II) with projected sales revenue of 118 million yuan, accounting for 1.05% of the 2024 annual revenue [1] - Irbesartan Dispersible Tablets with projected sales revenue of 110 million yuan, accounting for 0.98% of the 2024 annual revenue [1]

Core Viewpoint - The company, China Resources Double Crane (华润双鹤), is participating in a national procurement process for drugs whose agreements have expired, with some of its products expected to be selected in this procurement [1][2]. Group 1: Company Performance - In the first three quarters of 2025, the sales revenue for Valsartan and Hydrochlorothiazide tablets was 426 million yuan, accounting for 5.14% of total revenue [1]. - Sales revenue for Nifedipine Controlled Release Tablets was 138 million yuan, representing 1.67% of total revenue [1]. - Sales revenue for Enoxaparin Sodium Injection was 119 million yuan, making up 1.43% of total revenue [1]. - Sales revenue for Nifedipine Sustained Release Tablets (II) was 108 million yuan, which is 1.30% of total revenue [1]. - Sales revenue for Irbesartan Dispersible Tablets was 79 million yuan, accounting for 0.95% of total revenue [1]. Group 2: Industry Context - The procurement process is expected to stabilize or further reduce prices, providing medical institutions with greater choice among selected suppliers, which helps ensure continuity in clinical medication and reduces risks associated with drug switching due to centralized procurement [2]. - Although the selection may lead to a decrease in overall sales amounts, it is anticipated to solidify existing market shares, with the company likely to enhance its market share due to its brand influence and reliable supply capabilities [2].

证券代码：600062 证券简称：华润双鹤 公告编号：临2026－009 华润双鹤药业股份有限公司 第十届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 同意公司为满足"十五五"战略发展需要，精准匹配患者临床需求，强化营销体系建设，推进营销资源整 合，组建营销管理中心。 11票同意，0票反对，0票弃权。 特此公告。 华润双鹤药业股份有限公司 公司第十届董事会第十七次会议的召开符合《公司法》和公司《章程》的有关规定。本次会议通知和材 料于2026年2月2日以邮件方式向全体董事发出，会议于2026年2月5日以通讯方式召开。出席会议的董事 应到11名，亲自出席会议的董事11名。 二、董事会会议审议情况 1、关于2026年境外佣金预算的议案 11票同意，0票反对，0票弃权。 2、关于组建营销管理中心的议案 一、董事会会议召开情况 董 事 会 2026年2月6日 ...

第十届董事会第十七次会议 2026 年 2 月 5 日 证券代码：600062 证券简称：华润双鹤 公告编号：临 2026－009 华润双鹤药业股份有限公司 第十届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 1、关于2026年境外佣金预算的议案 11 票同意，0 票反对，0 票弃权。 2、关于组建营销管理中心的议案 同意公司为满足"十五五"战略发展需要，精准匹配患者临床需 求，强化营销体系建设，推进营销资源整合，组建营销管理中心。 11 票同意，0 票反对，0 票弃权。 特此公告。 华润双鹤药业股份有限公司 董 事 会 一、董事会会议召开情况 公司第十届董事会第十七次会议的召开符合《公司法》和公司《章 程》的有关规定。本次会议通知和材料于 2026 年 2 月 2 日以邮件方 式向全体董事发出，会议于 2026 年 2 月 5 日以通讯方式召开。出席 会议的董事应到 11 名，亲自出席会议的董事 11 名。 二、董事会会议审议情况 2026 年 2 月 6 日 ...